Table 4. Changes in perception of physicians of the expected contribution of genetic component for each domain of cancer, rare disease, prenatal screening, disease risk prediction and PGx at pre-test and post-test questionnaire.
| Clinical Fields | Pre-test questionnaire Score | Post-test questionnaire Score | Diff (Post-test questionnaire—Pre-test questionnaire) | p value* | |
|---|---|---|---|---|---|
| mean (SD) | mean (SD) | n | mean (SD) | ||
| Cancer target therapy | 4.35 (0.78) | 4.57. (0.67) | 69 | 0.26 (0.83) | 0.01 |
| Rare disease diagnosis | 4.43 (0.83) | 4.66. (0.63) | 70 | 0.23 (0.92) | 0.0287 |
| Prenatal screening | 4.16 (0.96) | 4.34 (0.8) | 69 | 0.22 (0.95) | 0.0852 |
| Chronic disease risk prediction | 3.61 (1.04) | 3.79 (1.03) | 70 | 0.17 (1.04) | 0.1583 |
| PGx | 4.1 (0.94) | 4.33 (0.81) | 69 | 0.26 (0.83) | 0.0104 |
* Wilcoxon rank sum test